Magazine Article | May 2, 2018

Lilly Uses Patient Awareness & Access To Cut Clinical Trial Timelines

Source: Life Science Leader

By Ed Miseta, Chief Editor, Clinical Leader

A clinical trial transformation is currently underway at Eli Lilly & Company. Two years ago, it was taking the company an average of 10.5 years to go from first patient dosed to actual product launch. The time it took to simply enroll patients in trials was averaging four years. That means 40 percent of the time a drug was in development was spent simply recruiting patients. There is a set amount of time that is spent treating patients and analyzing data. Oftentimes that cannot be changed. But enrollment was one area where the company felt improvements could be made.

“The situation had to change,” says Anne White, Lilly’s VP of next generation development and project management. “We knew we had to find a way to get our medicines to patients faster.” CEO at the time, John Lechleiter, told his leadership team, “I want to change this dynamic. We need to be fast along with having a great portfolio. How do we make that happen?” According to White, for the past two years the company has worked toward turning his vision into reality.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader